Tuesday, April 14, 2026
IEA: World oil supply to drop 1.5M bpd in 2026
The International Energy Agency (IEA) estimated on Tuesday that global oil supply will fall by 1.5 million barrels per day (bpd) in 2026, compared to an increase of 1.1 million bpd forecast in last month's report. Meanwhile, demand is seen dropping by 80,000 bpd, down from a rise of 640,000 bpd previously, while supply is expected to exceed demand by 410,000 bpd, compared to 2.46 million bpd projected in March.
The IEA said that oil, fuel and natural gas liquid traffic through the Strait of Hormuz decreased to 3.8 million bpd in early April, down from over 20 million bpd before the start of the United States-Israel military campaign against Iran. It argued that restoring free navigation through the strait, which is currently also blockaded by the US, is the "single most important variable" in resolving the current energy crisis.
https://breakingthenews.net/Article/IEA:-World-oil-supply-to-drop-1.5M-bpd-in-2026/66062726
PolyPeptide Studies Strategic Options as Private Equity Circles
PolyPeptide Group AG and its billionaire shareholder Frederik Paulsen are working on strategic options for the company.
The Swiss contract drugmaker’s review is at an early stage and “there can be no assurances” that it will result in any transaction or other outcome, the company said in a statement on Tuesday. PolyPeptide said it is “well positioned” to achieve its ambition to double 2023 revenue by 2028.
Novo Nordisk partners with OpenAI to speed drug development
Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely lucrative weight-loss drug market, said on Tuesday it is partnering with OpenAI to deploy artificial intelligence across its business, from drug discovery to manufacturing and commercial operations.
The maker of Wegovy and Ozempic said the partnership would use OpenAI's technology to analyse complex datasets, identify promising drug candidates and improve efficiency in manufacturing, supply chains, distribution and corporate operations.
Drugmakers are increasingly using AI https://www.reuters.com/legal/litigation/drugmakers-turn-ai-speed-trials-regulatory-submissions-2026-01-26/ to streamline the more tedious parts of drug development, from finding clinical trial participants and selecting sites to preparing regulatory filings, though industry executives say the technology has not yet fully delivered on the harder task of discovering major new molecules.
Novo is seeking new ways https://www.reuters.com/sustainability/boards-policy-regulation/novo-nordisk-appoints-mars-ceo-board-observer-2026-03-26/ to regain ground in an intensifying obesity-drug battle https://www.reuters.com/business/healthcare-pharmaceuticals/pills-tiktok-weight-loss-apps-consumer-driven-future-glp-1s-2025-12-29/ with Indianapolis-based Lilly, which this month won U.S. approval https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-weight-loss-pill-wins-us-approval-2026-04-01/ for its weight-loss pill Foundayo after Novo launched
https://www.reuters.com/sustainability/boards-policy-regulation/novo-nordisk-sell-wegovy-pill-us-self-pay-patients-starting-149-per-month-2026-01-05/ oral Wegovy in January. Analysts expect annual revenue from weight-loss drugs to exceed $100 billion in the next decade.
Novo did not disclose financial terms of the agreement. It said pilot programmes would begin across research and development, manufacturing and commercial operations, with full integration planned by the end of 2026.
Novo said OpenAI will also help train its global workforce, increasing AI literacy and boosting productivity across departments.
TRAINING, NOT REPLACING
"The aim here is not replacing our scientists. It's about supercharging them," CEO Mike Doustdar said in an interview.
Doustdar said the partnership was not intended to cut Novo's current workforce, but to lift productivity and curb the pace of future hiring.
He said AI would help employees work faster and more effectively, reducing the need to grow headcount as much as in the past. Shortly after taking over as CEO last year, Doustdar announced a restructuring https://www.reuters.com/business/novo-nordisk-slashes-9000-jobs-slim-down-fierce-weight-loss-drug-battle-2025-09-10/ that cut 9,000 jobs.
https://finance.yahoo.com/sectors/healthcare/articles/wegovy-maker-novo-nordisk-partners-060425868.html